Viktor Wintzell

1.1k total citations · 1 hit paper
24 papers, 634 citations indexed

About

Viktor Wintzell is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Epidemiology. According to data from OpenAlex, Viktor Wintzell has authored 24 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Surgery and 6 papers in Epidemiology. Recurrent topics in Viktor Wintzell's work include Diabetes Treatment and Management (10 papers), Metabolism, Diabetes, and Cancer (5 papers) and Gastroesophageal reflux and treatments (4 papers). Viktor Wintzell is often cited by papers focused on Diabetes Treatment and Management (10 papers), Metabolism, Diabetes, and Cancer (5 papers) and Gastroesophageal reflux and treatments (4 papers). Viktor Wintzell collaborates with scholars based in Sweden, Denmark and United States. Viktor Wintzell's co-authors include Björn Pasternak, Henrik Svanström, Jonas F. Ludvigsson, Mads Melbye, Peter Ueda, Björn Eliasson, Christian Jonasson, Soffia Guðbjörnsdóttir, Kristian Hveem and Stefan Franzén and has published in prestigious journals such as JAMA, Hepatology and Diabetes Care.

In The Last Decade

Viktor Wintzell

24 papers receiving 629 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study

2024 57 citations Björn Pasternak, Viktor Wintzell et al. BMJ profile →

Peers

Countries citing papers authored by Viktor Wintzell

Since Specialization

Citations

This map shows the geographic impact of Viktor Wintzell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Viktor Wintzell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Viktor Wintzell more than expected).

Fields of papers citing papers by Viktor Wintzell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Viktor Wintzell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Viktor Wintzell. The network helps show where Viktor Wintzell may publish in the future.

Co-authorship network of co-authors of Viktor Wintzell

This figure shows the co-authorship network connecting the top 25 collaborators of Viktor Wintzell. A scholar is included among the top collaborators of Viktor Wintzell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Viktor Wintzell. Viktor Wintzell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children 2025 ·JAMA Pediatrics ·Viktor Wintzell, Philip Brenner, Linda Halldner, Samuel Rhedin, Tong Gong, Catarina Almqvist	3
2	Use of inhaled corticosteroids and the risk of hospitalisation for pneumonia in children with asthma: a nationwide cohort study 2024 ·Thorax ·(unknown), Samuel Rhedin, Catarina Almqvist, Viktor Wintzell	1
3	Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study 2024 ·European Heart Journal - Cardiovascular Pharmacotherapy ·(unknown), Jonas Söderling, Anders Hviid, Björn Eliasson, Soffia Guðbjörnsdóttir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Björn Pasternak, Peter Ueda	4
4	Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study breakdown → 2024 ·BMJ ·Björn Pasternak, Viktor Wintzell, Anders Hviid, Björn Eliasson, Soffia Guðbjörnsdóttir, Christian Jonasson, Kristian Hveem, Henrik Svanström, Mads Melbye, Peter Ueda	57
5	Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study 2023 ·Hepatology ·Arvid Engström, Viktor Wintzell, Mads Melbye, Henrik Svanström, Björn Eliasson, Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Anders Hviid, Peter Ueda, Björn Pasternak	31
6	Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study 2023 ·Clinical Gastroenterology and Hepatology ·Peter Ueda, Viktor Wintzell, Mads Melbye, Björn Eliasson, (unknown), Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Henrik Svanström, Anders Hviid, Björn Pasternak	19
7	Association between proton pump inhibitor use and risk of pneumonia in children: nationwide self-controlled case series study in Sweden 2022 ·BMJ Open ·(unknown), Henrik Svanström, Viktor Wintzell, Jonas F. Ludvigsson, Björn Pasternak	7
8	Sodium–Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study 2022 ·Diabetes Care ·(unknown), Viktor Wintzell, Mads Melbye, Anders Hviid, Björn Eliasson, Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Henrik Svanström, Björn Pasternak, Peter Ueda	22
9	Selection of Comparator Group in Observational Drug Safety Studies: Alternatives to the Active Comparator New User Design 2022 ·Epidemiology ·Viktor Wintzell, Henrik Svanström, Björn Pasternak	7
10	Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study 2021 ·Diabetologia ·Peter Ueda, Viktor Wintzell, Mads Melbye, Björn Eliasson, Ann‐Marie Svensson, Stefan Franzén, Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Henrik Svanström, Björn Pasternak	17
11	The comparative cardiovascular and renal effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A Scandinavian cohort study 2021 ·Diabetes Obesity and Metabolism ·Peter Ueda, Viktor Wintzell, Elisabeth Dahlqwist, Björn Eliasson, Ann‐Marie Svensson, Stefan Franzén, Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Mads Melbye, Anders Hviid, Henrik Svanström, Björn Pasternak	22
12	Data Mining for Adverse Events of Tumor Necrosis Factor-Alpha Inhibitors in Pediatric Patients: Tree-Based Scan Statistic Analyses of Danish Nationwide Health Data 2020 ·Clinical Drug Investigation ·Viktor Wintzell, Henrik Svanström, Mads Melbye, Jonas F. Ludvigsson, Björn Pasternak, Martin Kulldorff	6
13	Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study 2020 ·BMJ ·Björn Pasternak, Viktor Wintzell, Mads Melbye, Björn Eliasson, Ann‐Marie Svensson, Stefan Franzén, Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Henrik Svanström, Peter Ueda	70
14	Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children 2020 ·JAMA Pediatrics ·Yunhan Wang, Viktor Wintzell, Jonas F. Ludvigsson, Henrik Svanström, Björn Pasternak	47
15	Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study 2020 ·Diabetes Care ·Björn Pasternak, Viktor Wintzell, Björn Eliasson, Ann‐Marie Svensson, Stefan Franzén, Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Mads Melbye, Henrik Svanström, Peter Ueda	50
16	Impact of variable look‐back periods on the incidence rates of chronic diseases using real world data 2020 ·Pharmacoepidemiology and Drug Safety ·Mats Rosenlund, Nils Ekström, (unknown), Viktor Wintzell, James H. Stark, Lina Titievsky	12
17	Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study 2019 ·BMJ ·Björn Pasternak, Peter Ueda, Björn Eliasson, Ann‐Marie Svensson, Stefan Franzén, Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Viktor Wintzell, Mads Melbye, Henrik Svanström	77
18	Association between use of azathioprine and risk of acute pancreatitis in children with inflammatory bowel disease: a Swedish–Danish nationwide cohort study 2019 ·The Lancet Child & Adolescent Health ·Viktor Wintzell, Henrik Svanström, Ola Olén, Mads Melbye, Jonas F. Ludvigsson, Björn Pasternak	26
19	Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study 2019 ·The Lancet. Gastroenterology & hepatology ·Viktor Wintzell, Henrik Svanström, Mads Melbye, Tine Jess, Ola Olén, Jonas F. Ludvigsson, Björn Pasternak	9
20	Healthcare Resource Use, Cost, and Sick Leave Following Kidney Transplantation in Sweden: A Population-Based, 5-Year, Retrospective Study of Outcomes: COIN 2018 ·Annals of Transplantation ·Bengt von Zur‐Mühlen, Viktor Wintzell, (unknown), Mats Rosenlund, (unknown), (unknown), Jonas Wadström	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact